Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Dynavax Technologies Corporation

Dynavax Technologies Corporation (DVAX) Stock Overview

Explore Dynavax Technologies Corporation’s financial performance, market position, analyst ratings, and future outlook.

DVAX●NASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$15.50
$0.00(0.00%)
U.S. Market is Open · 11:32

Dynavax Technologies Corporation (DVAX)

Meyka AI Score

Z

Key Financials

Market Cap1.8B
P/E Ratio-40.79
EPS (TTM)$-0.37
ROE-0.10%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$12.13

DVAX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Dynavax Technologies Corporation (NASDAQ: DVAX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Dynavax Technologies Corporation's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of DVAX on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $12.13 for the NASDAQ listing.

Key metrics behind Dynavax Technologies Corporation's NASDAQ-traded stock include a P/E ratio of -40.79 and a market capitalization of 1.8B. Combined with our AI analysis, these give both institutional and retail investors a clear view of DVAX on the NASDAQ.

Price Performance (NASDAQ: DVAX)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
43.52%
6-Month Change
64.72%
Year-to-Date (YTD) Change
0.78%
1-Year Change
13.22%
3-Year Change
58.81%
5-Year Change
51.81%
All-Time (Max) Change
-83.51%

Contact Information

https://www.dynavax.com
510 848 5100
2100 Powell Street, EmeryVille, CA, 94608

Company Facts

4,050 Employees
IPO DateFeb 19, 2004
CountryUS

Frequently Asked Questions